top of page
  • Recruiting

NCT04688853: Phase 1 - A Study to Investigate the Safety and Efficacy of TEG002 in RRMM

Updated: May 25, 2022


NCT04688853: Phase 1 - A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients


TEG002

This is a single arm, open-label, multicenter phase I study to assess the safety, tolerability and preliminary efficacy of autologous T cells transduced with a specific γδTCR, i.e. TEG002, in a dose escalation and expansion study in relapsed/refractory Multiple Myeloma patients.


Sponsor

Gadeta B.V.

 

ClinicalTrials.gov Identifier: NCT04688853


Official Title: A Phase I Study to Investigate the Safety, Tolerability and Preliminary Efficacy of TEG002 Infusion in Relapsed/Refractory Multiple Myeloma Patients


First Posted: December 30, 2020


Click here for details on ClinicalTrials.gov

 
 

Location

United States, Massachusetts


Commentaires


Posts Archive
bottom of page